IMU 0.00% 3.6¢ imugene limited

huge deal

  1. 4,996 Posts.
    In a deal that may bring a flood of new capital to a Australian biotechnology firm, Imugene will collaborate with pharmaceutical giant Merial to develop three new livestock products with huge global markets.
    The deal is a quantum leap for the company.

    The fact that Merial chose Imugene validates Imugene's patented Adenovirus platform.

    Dr. Marcus Remmers, Head of Business Development at Merial, said, “We are very excited
    about the adenovirus vector as a potential delivery platform. Given the current results and the
    large increases in productivity evidenced from the initial trials, the market potential for these
    products can be very large, both in terms of providing an alternative to in-feed antibiotics and
    safely improving profitability for producers.”

    The Imugene Group owns a diverse portfolio of innovative animal health products to tap into
    the US$10 billion per annum health products market for production and companion animals
    worldwide. The production animal products utilize the Imugene Groups patented adenovirus
    vector delivery systems. In trials to date the biological productivity enhancers have
    demonstrated consequential increases in productivity and are proven to be residue free. The
    vaccines against several viral diseases of poultry and pigs have successfully provided
    protection against disease challenge.
watchlist Created with Sketch. Add IMU (ASX) to my watchlist
(20min delay)
Mkt cap ! $159.3M
Open High Low Value Volume
3.6¢ 3.6¢ 3.5¢ $120.9K 3.363M

Buyers (Bids)

No. Vol. Price($)
11 2587560 3.5¢

Sellers (Offers)

Price($) Vol. No.
3.6¢ 4178814 19
View Market Depth
Last trade - 11.37am 08/07/2020 (20 minute delay) ?
0.000 ( 2.51 %)
Open High Low Volume
3.6¢ 3.6¢ 3.5¢ 553259
Last updated 11.57am 08/07/2020 (live) ?
IMU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.